Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Bosutinib, a dual Src/Abl tyrosine kinase inhibitor (TKI), has shown potent activity against chronic myeloid leukemia (CML). This phase 1/2 study evaluated the efficacy and safety of once-daily bosutinib 500 mg in leukemia patients after resistance/intolerance to imatinib. The current analysis inclu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Khoury, H. Jean, Cortes, Jorge E., Kantarjian, Hagop M., Gambacorti-Passerini, Carlo, Baccarani, Michele, Kim, Dong-Wook, Zaritskey, Andrey, Countouriotis, Athena, Besson, Nadine, Leip, Eric, Kelly, Virginia, Brümmendorf, Tim H.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2012
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916559/
https://ncbi.nlm.nih.gov/pubmed/22371878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-11-390120
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items